Lonza: expansion at Tampa site
Lonza has announced plans to expand its inhalation services via added capacity at its Tampa, Florida site. The expansion involves additional inhalation testing capacity at the facility, specialized in development, clinical, and commercial manufacturing of small-molecule-based therapies targeting respiratory diseases and disorders, such as cancer, asthma, and chronic obstructive pulmonary disease (COPD).
Jeff Williamson (associate director of product development for small molecules at Lonza Tampa) said, “Increasing our capabilities in providing solutions for inhaled products will benefit our existing and future customers. The growth of our Inhalation service network will ensure that our team continues to deliver solutions and support necessary for advancing dry powder inhaler products for pulmonary delivery that often face solubility and bioavailability challenges.”